Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 11/20 | 0.45 |
| ▸ | CTSS | P25774 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000144 | 1.00 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL23833052 | 1.00 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL18866617 | 0.90 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL9396774 | 0.90 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL28981403 | 0.87 | CA1 (0.44) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL26003343 | 0.86 | CA1 (0.41) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL18494114 | 0.86 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL25702483 | 0.85 | CA1 (0.43) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL23833107 | 0.84 | CA1 (0.47) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL21510806 | 0.84 | CA2 (0.47) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023057882-A1 | COMBINATIONS OF AZALACTAM COMPOUNDS WITH A PD-1 AXIS BINDING ANTAGONIST FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022242750-A1 | PIPERAZINE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-11-24 | — | — | WO | disclosed |
| CN-111635335-B | Synthesis method of chiral gamma-amino acid and chiral gamma-amino acid synthesized by adopting method | 上海交通大学 | 2021-07-13 | — | — | CN | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| CN-111635335-A | Synthesis method of chiral gamma-amino acid and chiral gamma-amino acid synthesized by adopting method | 上海交通大学 | 2020-09-08 | — | — | CN | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-6838074-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | CA1 1233/4885CA2 3205/4885CA7 1216/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CA1 4498/4885CA2 3900/4885CA7 193/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | CA1 1233/4885CA2 3205/4885CA7 1216/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CA1 4498/4885CA2 3900/4885CA7 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.